Servier Pharmaceuticals shared a post on LinkedIn:
“We’re looking forward to attending ASCO26 and sharing our latest research across a range of rare cancers, including IDH-mutated glioma and adenoid cystic carcinoma with the oncology community.
Read the full announcement here.”
Other articles about ASCO on OncoDaily.